WO2000033815A1 - Preparations poudreuses en aerosol contenant un fongicide - Google Patents
Preparations poudreuses en aerosol contenant un fongicide Download PDFInfo
- Publication number
- WO2000033815A1 WO2000033815A1 PCT/JP1999/006852 JP9906852W WO0033815A1 WO 2000033815 A1 WO2000033815 A1 WO 2000033815A1 JP 9906852 W JP9906852 W JP 9906852W WO 0033815 A1 WO0033815 A1 WO 0033815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antifungal agent
- aerosol
- powder
- nitrate
- fungicide
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000855 fungicidal effect Effects 0.000 title abstract 4
- 239000000417 fungicide Substances 0.000 title abstract 4
- 239000000843 powder Substances 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical class CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003380 propellant Substances 0.000 claims abstract description 10
- 229940121375 antifungal agent Drugs 0.000 claims description 45
- 239000003429 antifungal agent Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 22
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical group O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims description 10
- 229960005040 miconazole nitrate Drugs 0.000 claims description 10
- 229910002651 NO3 Inorganic materials 0.000 claims description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 5
- -1 ratconazole Chemical compound 0.000 claims description 5
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960003645 econazole nitrate Drugs 0.000 claims description 3
- 229960003483 oxiconazole Drugs 0.000 claims description 3
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 claims description 2
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 claims description 2
- 229940043276 diisopropanolamine Drugs 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960004718 sulconazole nitrate Drugs 0.000 claims description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 238000001035 drying Methods 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 150000001412 amines Chemical class 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 208000007163 Dermatomycoses Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N sec-butylidene Natural products CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- JOTMFOWEVMXFHO-UHFFFAOYSA-N 2-aminoethyl benzoate Chemical compound NCCOC(=O)C1=CC=CC=C1 JOTMFOWEVMXFHO-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Definitions
- the present invention relates to an aerosol formulation containing an antifungal agent, and more particularly, to an aerosol formulation containing an antifungal agent containing a powder component for the purpose of drying an affected part and promoting healing. It is about.
- Fungal infections on the skin include tinea, candidiasis, and starchy dermatitis.Dry skin symptoms include erythema and desquamation, and wet forms with erythema, vesicles, maceration, and erosion There is. Antifungal agents are used in these treatments, and many formulations have been developed, including ointments, creams, solutions, and aerosols. Under these circumstances, powdered aerosol formulations containing antifungal agents and powdered components have been developed with the aim of drying wet moistened affected areas to speed treatment and prevent secondary infection. JP-A-5-246643 discloses a dry spray type antifungal-containing composition. Japanese Patent Application Laid-Open No. 8-129964 discloses a powder aerosol containing an antifungal agent which is difficult to fall off the skin.
- azolic drugs such as miconazole nitrate, econazole nitrate, and oxyconazole nitrate, which have an antibacterial spectrum against not only ringworm but also Candida, have been awarded for fungal infections. Have been used. However, these drugs have extremely low solubility of base components generally used in external preparations in solvents such as water and alcohol. For this reason, Japanese Patent Application Laid-Open No. 4-173733 describes an antifungal external preparation prepared by dissolving an antifungal agent in an external base using amines such as diphenhydramine, lidocaine, and diethanolamine. Is disclosed.
- this technology dissolves an antifungal agent in a large amount of an external base, and requires a quick drying property such as a powder aerosol formulation.
- Antifungals present in aerosol formulations in crystalline form are sprayed in crystalline form, so their absorption and penetration into the stratum corneum are low and the actual therapeutic effect is not sufficient.
- the antifungal agent is settled at the bottom of the aerosol can in a crystalline state, if the shaking before use is insufficient, the antifungal agent in the aerosol can is not evenly dispersed and The concentration cannot be applied, and a sufficient therapeutic effect cannot be expected.
- the present invention provides an antifungal agent-containing powder aerosol formulation in which an antifungal agent is present in a dissolved state in a powder aerosol formulation in which only a small amount of a dissolved component is required because quick drying is required. Disclosure of the invention
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems. As a result, the combination of a lower alcohol with at least one of isopropanolamines and amylamines in a fungal preparation, The present inventors have found that the antifungal agent can be uniformly present in the aerosol formulation in a dissolved state even when the propellant is filled by setting the predetermined amount, and the present invention has been completed.
- the present invention is a powdered aerosol formulation containing an antifungal agent, which comprises an antifungal agent, a lower alcohol, at least one of isopropanolamines and amylamines, and a propellant.
- an azole antifungal agent which is known to be hardly soluble is preferably used.
- azo-based antifungal agents particularly preferred are methanolic nitrate, econazole nitrate, oxyconazole nitrate, sulconazole nitrate, ketoconazole, ratconazole, and itraconazole, which are hardly soluble in ethanol.
- the compounding amount of the antifungal agent is 0.03% to 5% by mass based on the total amount of the preparation. These are determined by considering the efficacy and safety of the drug.
- the lower alcohol is effective as a component of a liquid base used for improving the adhesion of the powder to the skin at the time of injection and dissolving the active ingredient.
- the lower alcohol is a monohydric alcohol having 1 to 3 carbon atoms, and examples thereof include methanol, ethanol, isopropanol, and denatured ethanol. Particularly, ethanol and isopropanol are preferred.
- These components dissolve the antifungal agent It has a relatively low boiling point and is effective as a quick-drying liquid base that is characteristic of powdered aerosols.
- the compounding amount is 1 to 20% by mass, preferably 3 to 15% by mass based on the total amount of the preparation. If the amount is less than 1%, the dissolution of the antifungal agent cannot be assisted, and if it is more than 20%, the quick-drying property as a powdery aerosol containing the antifungal agent cannot be realized.
- isopropanolamines and amylamines are a component that helps the solubility of the antifungal agent.
- Other amines cannot achieve the purpose of the present invention.
- isopropanolamines include monoisopropanolamine, diisopropanolamine, and triisopropanolamine.
- amylamines include normal amylamine, isoamylamine, neoamylamine and the like.
- the content of these substances is 0.001 to 5% by mass based on the total amount of the preparation. Preferably it is 0.01 to 3% by mass. If the content is less than 0.001% by mass, it is difficult to achieve the above object, and if the content is more than 5% by mass, safety to the skin is concerned.
- the powder component added to make a powder aerosol enhances the adhesion of the active ingredient to the skin, improves the dryness of wet parts, improves slipperiness and lubricity, and enhances usability. It is added for the purpose of dissolving or considering the suitability for the production of powder aerosols.
- inorganic powders such as gay anhydride, magnesium silicate, talc, kaolin, aerosil, mica, zinc oxide, titanium oxide, magnesium oxide, magnesium carbonate, calamine, magnesium aluminate metasilicate
- organic powders such as corn starch, potato starch, nylon powder, polyethylene powder, polystyrene powder, and cellulose powder. These powder components are used alone or in combination of two or more.
- the compounding amount of the powder component is 0.5 to 15% by mass, preferably 2 to 10% by mass based on the total amount of the preparation. If the amount is less than 0.5% by mass, it is difficult to satisfy the above-mentioned object, and if the amount is more than 15% by mass, injection clogging with powder occurs, which is not preferable.
- a liquefied gas is used as the propellant. Among them, fossil oil gas is preferable, and dimethyl ether may be added.
- the amount of the propellant is 65 to 98% by mass, preferably 75 to 95% by mass, based on the total amount of the preparation.
- the liquefied petroleum gas here includes not only ordinary propane, isobutane and normal butane but also a combination of components such as normal pentane, isopentane and neopentane.
- the antifungal agent although not particularly limited, local anesthetics (such as lidocaine and aminoethyl benzoate), anti-inflammatory agents (such as allantoin and zinc oxide), and disinfectants (such as chloride Decalinium, benzalkonium chloride, etc.), anti-histamines (diphenhydramine, chlorpheniramine maleate, etc.), fresheners (1-menthol, d-1 camphor, etc.) can be added.
- absorption of active ingredients improvement of permeability, improvement of skin safety, improvement of dispersion stability of powder in aerosol formulation, improvement of spreadability of powder and active ingredient at the time of injection, improvement of feeling of use, etc.
- active ingredients improvement of permeability, improvement of skin safety, improvement of dispersion stability of powder in aerosol formulation, improvement of spreadability of powder and active ingredient at the time of injection, improvement of feeling of use, etc.
- the following can be blended.
- silicone oils such as methylpolysiloxane
- hydrocarbons such as liquid paraffin and squalane
- higher fatty acid esters such as isopropyl myristate, octyldodecyl myristate, and butyl stearate
- vegetable oils such as olive oil and castor oil
- Animal oils such as beeswax and squalene
- nonionic surfactants such as sorbitan sesquioleate and polyglycerin fatty acid ester
- Aerosols were manufactured according to the formulations shown in Tables 1 and 2 by a conventional method.
- Dissolution The liquid content in the glass pressure bottle is one liquid, and the antifungal is dissolved. Undissolved: Antifungal agent has precipitated as crystals or oil at the bottom of the liquid content of the glass pressure bottle.
- the aerosol of the example or comparative example shown in Table 3 was spray-coated on a silicone rubber film (2.5 cm x 5 cm) and stored in an environment of 35% humidity and 35% humidity. After a lapse of time, the concentration of miconazole nitrate in the silicone rubber film was measured, and the release of miconazole nitrate from the base material of the preparation was evaluated. The test was repeated three times, and the average was determined. The results are shown in Table 3.
- Release rate% (silicon:! 'Concentration of miconazo nitrate in film'-film amount of silicon film 'conic acid miconazole nitrate'-amount) X 100 Test Example 3 [Evaluation of keratin retention]
- the aerosol of the example or comparative example shown in Table 3 was spray-applied to the abdomen of a hairless rat, and after 6 hours, the application residue on the skin was wiped off with a rayon cloth soaked with an alcohol solution, and then applied to a transparent adhesive tape.
- the stratum corneum of the applied part was peeled off, and the amount of miconazole nitrate contained therein was measured to determine the amount of drug stored in the stratum corneum. The test was repeated three times and the average was determined. Table 3 shows the results. Table 3
- Example 6 the release of miconazole nitrate from the base material was high, and in experiments using rats, the amount of miconazole nitrate stored in the keratin, which is the location of the dermatomycosis fungi, was high and high. A therapeutic effect can be expected. As for the usability, it dried immediately after the spray application, giving a smooth feeling. In Comparative Example 9, since it is jetted in a crystalline state, the release from the base is low, the amount stored in the stratum corneum is small, and a sufficient therapeutic effect cannot be expected. Industrial applicability
- the antifungal agent-containing powder aerosol formulation of the present invention allows the antifungal agent to be present in a dissolved state in the aerosol, so that the drug has a high permeability to the keratin and a consistently uniform drug injection. It can be applied, and it dries quickly and has a good feeling of use. Therefore, it is possible to provide a powder aerosol preparation which exhibits excellent therapeutic effects and a feeling of use for fungal skin diseases such as tinea, candily, and starch.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des préparations poudreuses en aérosol qui contiennent: (a) un fongicide; (b) un alcool de faible poids moléculaire; (c) au moins un élément choisi parmi les isopropanolamines et les amylamines; (d) un composant poudreux; et (e) un gaz de propulsion. Dans ces préparations, le fongicide peut se présenter sous forme dissoute en raison de la présence des amines spécifiques. On peut pulvériser ces préparations afin d'obtenir, de manière continue, une concentration uniforme de médicaments. Par ailleurs, ces préparations, qui présentent un remarquable pouvoir de pénétration dans la couche cornée de l'épiderme, peuvent sécher rapidement, ce qui a pour effet de stimuler leurs effets thérapeutiques en séchant les parties concernées.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14159/00A AU1415900A (en) | 1998-12-10 | 1999-12-07 | Fungicide-containing powdery aerosol preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35179998 | 1998-12-10 | ||
JP10/351799 | 1998-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000033815A1 true WO2000033815A1 (fr) | 2000-06-15 |
Family
ID=18419694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/006852 WO2000033815A1 (fr) | 1998-12-10 | 1999-12-07 | Preparations poudreuses en aerosol contenant un fongicide |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1415900A (fr) |
WO (1) | WO2000033815A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014026213A1 (fr) * | 2012-08-17 | 2014-02-20 | Gebro Holding Gmbh | Composition antiseptique |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6183117A (ja) * | 1984-09-28 | 1986-04-26 | Sumitomo Chem Co Ltd | エアゾ−ル剤 |
JPS62273912A (ja) * | 1986-05-21 | 1987-11-28 | Kao Corp | 人体塗布用エアゾ−ル剤 |
JPH04173734A (ja) * | 1990-11-07 | 1992-06-22 | Nitsusui Seiyaku Kk | 抗真菌性外用剤 |
US5262150A (en) * | 1990-09-26 | 1993-11-16 | L'oreal | Antifungus composition in dry spray form |
JPH07242567A (ja) * | 1994-03-04 | 1995-09-19 | Showa Denko Kk | 抗真菌外用剤 |
JPH0812964A (ja) * | 1994-07-01 | 1996-01-16 | Kobayashi Pharmaceut Co Ltd | 粉末エアゾール組成物 |
JPH0840899A (ja) * | 1994-07-29 | 1996-02-13 | Tokyo Tanabe Co Ltd | 硝酸オキシコナゾールのエアゾール剤 |
-
1999
- 1999-12-07 WO PCT/JP1999/006852 patent/WO2000033815A1/fr active Application Filing
- 1999-12-07 AU AU14159/00A patent/AU1415900A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6183117A (ja) * | 1984-09-28 | 1986-04-26 | Sumitomo Chem Co Ltd | エアゾ−ル剤 |
JPS62273912A (ja) * | 1986-05-21 | 1987-11-28 | Kao Corp | 人体塗布用エアゾ−ル剤 |
US5262150A (en) * | 1990-09-26 | 1993-11-16 | L'oreal | Antifungus composition in dry spray form |
JPH04173734A (ja) * | 1990-11-07 | 1992-06-22 | Nitsusui Seiyaku Kk | 抗真菌性外用剤 |
JPH07242567A (ja) * | 1994-03-04 | 1995-09-19 | Showa Denko Kk | 抗真菌外用剤 |
JPH0812964A (ja) * | 1994-07-01 | 1996-01-16 | Kobayashi Pharmaceut Co Ltd | 粉末エアゾール組成物 |
JPH0840899A (ja) * | 1994-07-29 | 1996-02-13 | Tokyo Tanabe Co Ltd | 硝酸オキシコナゾールのエアゾール剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014026213A1 (fr) * | 2012-08-17 | 2014-02-20 | Gebro Holding Gmbh | Composition antiseptique |
Also Published As
Publication number | Publication date |
---|---|
AU1415900A (en) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3268852B2 (ja) | フエルビナクを含有する製剤学的組成物 | |
ES2391782T3 (es) | Composición monofásica formadora de una película para la administación tópica | |
CA2444533C (fr) | Excipient pharmaceutique | |
KR20070050040A (ko) | 약제학적으로 우수한 국소용 무수 에어로졸 포움 | |
WO2000023051A1 (fr) | Compositions aerosol comprenant un onguent et leur procede de preparation | |
WO2008038140A2 (fr) | Vecteur expansible à base de polypropylène glycol et compositions pharmaceutiques associées | |
WO2007070695A2 (fr) | Compositions de fluidification et procede pour administrer par voie cutanee des medicaments | |
JP2013501780A (ja) | 爪の真菌感染を治療するための組成物及び方法 | |
JP2021515812A (ja) | 抗真菌液剤およびフットワイプ | |
JP2009519956A (ja) | 薬物の皮膚送達のための組成物および方法 | |
JP4438147B2 (ja) | 抗真菌剤含有粉末エアゾール製剤 | |
JPH0377820A (ja) | エアゾール剤 | |
WO2000033815A1 (fr) | Preparations poudreuses en aerosol contenant un fongicide | |
JP2797401B2 (ja) | 爪用抗真菌剤組成物 | |
TW202239430A (zh) | 外用劑組合物 | |
WO1994002126A1 (fr) | Compositions et procedes pour le traitement topique des lesions de la peau | |
KR100288190B1 (ko) | 피록시캄 함유 알콜성 하이드로겔 조성물 | |
JP2001097848A (ja) | 外用剤組成物 | |
JP5341397B2 (ja) | エアゾール組成物 | |
JP2001226258A (ja) | 粉末エアゾール組成物 | |
WO2024024520A1 (fr) | Composition pour préparation externe | |
TW202416934A (zh) | 外用劑組合物 | |
JP2024018959A (ja) | 外用剤組成物 | |
JPS63141918A (ja) | かゆみ止め用エアゾ−ル組成物 | |
KR100405920B1 (ko) | 고분자 화합물을 포함하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 14159 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |